Zevra Therapeutics, Inc. Unamortized Debt Issuance Expense
Zevra Therapeutics, Inc. (ZVRA) had Unamortized Debt Issuance Expense of $4.00 million as of 2016-06-30, per its 10-Q filed 2016-08-11.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2017-03-10
- 2016-06-30: Unamortized Debt Issuance Expense $4.00M.
- 2016-03-31: Unamortized Debt Issuance Expense $4.20M.
- 2015-12-31: Unamortized Debt Issuance Expense $1.10M; Unamortized Debt Issuance Expense as first filed $1.13M.
- 2015-09-30: Unamortized Debt Issuance Expense $1.22M.
| Period end | Unamortized Debt Issuance Expense | Unamortized Debt Issuance Expense as first filed |
|---|---|---|
| 2016-06-30 | $4.00M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $4.20M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $1.10M 10-K · filed 2017-03-10 | $1.13M 10-K · filed 2016-03-16 |
| 2015-09-30 | $1.22M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $1.30M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $1.38M 10-Q · filed 2015-05-29 | |
| 2014-12-31 | $1.47M 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |